© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
February 19, 2022
Three immune cell-related factors appear to impact response or lack of response to treatment with nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma.
Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.
February 18, 2022
Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.
Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.
Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT and percent change in lesion number may be associated with overall survival in patients with metastatic genitourinary malignancies.
An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.
Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.
Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.
Tanya Dorff, MD, discusses the introduction of chimeric antigen receptor T-cell therapy into the prostate cancer landscape.
Utilizing 18F-rhPSMA-7.3 imaging, detection rates for prostate cancer recurrence were favorable in the phase 3 SPOTLIGHT study.